The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial

Background: Tocilizumab and baricitinib are considered standard treatments for hospitalized COVID-19 patients with an inflammatory status. However, the effects of co-administering these medications aiming for more rapid patient recovery are controversial among practitioners. The potential benefits i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dastan, Farzaneh, Jamaati, Hamidreza, Barati, Saghar, Varmazyar, Shahrzad, Yousefian, Sahar, Niknami, Elmira, Tabarsi, Payam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620525/
https://www.ncbi.nlm.nih.gov/pubmed/37927607
http://dx.doi.org/10.3389/fphar.2023.1265541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620525/
https://www.ncbi.nlm.nih.gov/pubmed/37927607
http://dx.doi.org/10.3389/fphar.2023.1265541

Ejemplares similares